4
Views
0
CrossRef citations to date
0
Altmetric
Cardiovascular Agents (Including Blood Products)

Patent Evaluation: Novel 5-bisaminomethylene-1,3-dioxane-4,6-diones as ACAT-inhibitors

Pages 729-730 | Published online: 02 Mar 2011
 

Summary

Novelty: Novel 5-bisaminomethylene-1,3-dioxane-4,6-diones are disclosed. These compounds are said to be ACAT inhibitors which possess antioxidant properties.

Biology: In vitro ACAT inhibition was determined (IC50 = 0.044 μM, 99% inhibition at a concentration of 26 μM). In vivo studies were undertaken on rats in order to establish inhibition of cholesterol absorption and percentage decrease of cholesterol in plasma (a 20 mg/kg dose induced a 62% decrease).

Chemistry: 5-[[[4-(Dimethylamino)phenyl]amino][(1-hexylheptyl)[[4-(2-methylpropyl)phenyl]-methyl]-amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione is one of seventy-seven specifically claimed compounds.

Structure:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.